首页> 外文期刊>Clinical & developmental immunology. >Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis.
【24h】

Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis.

机译:原发性胆汁性肝硬化患者抗线粒体抗体的系列分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Antimitochondrial antibodies (AMAs) are the classic serologic marker in primary biliary cirrhosis (PBC). However, there have been only limited attempts to study changes in titer or isotype analysis of such AMAs in patients followed for long periods of time. We took advantage of stored sera from well-characterized patients with PBC followed for a period of 7-28 years (mean duration of 13.5 years). Immunoblot and enzyme-linked immunosorbant assays were performed against PDC-E2, BCOADC-E2 and OGDC-E2 as well as isotype analysis of antigen-specific IgG, IgA and IgM antibodies against each of these mitochondrial autoantigens. Sera were analyzed for total IgG, IgA and IgM by radial immunodiffusion. The sera titer of AMAs was significantly higher in younger patients with PBC. Indeed, age of onset of clinical PBC was a significant predictor for the highest values of sera AMAs. In contrast, the AMA titer did not significantly change over time in this prolonged longitudinal study. The total sera levels of the individual immunoglobulins did not show a time-dependent change, when based on age of onset of the disease. Higher titers of AMAs were noted in the younger patients. Furthermore, despite this long follow-up, there was no evidence for a significant change in AMA levels; also, levels were not influenced by drug therapy used during the period of observation.
机译:抗线粒体抗体(AMAs)是原发性胆汁性肝硬化(PBC)的经典血清学标志物。然而,只有有限的尝试来研究长期随访的患者中此类AMA的效价或同种型分析的变化。我们充分利用了特征明确的PBC患者的血清,随访7-28年(平均病程13.5年)。针对PDC-E2,BCOADC-E2和OGDC-E2进行了免疫印迹和酶联免疫吸附测定,以及针对每种线粒体自身抗原的抗原特异性IgG,IgA和IgM抗体的同种型分析。通过放射免疫扩散分析血清的总IgG,IgA和IgM。年轻的PBC患者的AMA血清滴度明显更高。确实,临床PBC的发病年龄是血清AMA最高值的重要预测因子。相反,在这项长期的纵向研究中,AMA滴度没有随时间显着变化。当基于疾病的发病年龄时,各个免疫球蛋白的总血清水平未显示出时间依赖性变化。在年轻患者中发现较高的AMAs滴度。此外,尽管进行了长时间的随访,但尚无证据表明AMA水平有明显变化。同样,在观察期间,水平不受药物治疗的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号